The meeting provides recommendations to the G20 and its Member States and international partners on the establishment of a R&D and manufacturing network for diagnostics
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
The combination will support clients in getting their end-to-end discovery and development programs delivered.
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
lAIH strives to introduce appropriate interventions for nurturing an AMR innovation ecosystem in the country through cohesive efforts across the innovation pyramid
New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator
Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
Subscribe To Our Newsletter & Stay Updated
